North China Pharmaceutical Group Corp-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:North China Pharmaceutical Group Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014101
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
North China Pharmaceutical Group Corp (NCPC) is a healthcare products provider that manufactures and distributes antibiotic bulks and formulations, vitamins and nutrition products. The company’s products comprise antibiotics, penicillin, amoxicillin, streptomycin sulfate, cefradine, 7-ADCA, vitamin C and vitamin B12. It offers its products in dosage forms of capsules, granules, injections, freeze-dried powder for injection, immunologic and biologic agent, nutrition supplement, tablets, veterinary and biocides products, powder for injection, antineoplastic agents, oral suspension and other formulations. The company markets its products across China. NCPC is headquartered in Shijiazhuang, China.

North China Pharmaceutical Group Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
North China Pharma Announces Private Placement Of Common Stock For US$466 Million 11
Debt Offering 12
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 12
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 13
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 14
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 15
North China Pharma Announces Public Offering Of Notes For US$73 Million 16
Acquisition 17
NCPC To Sell North China Pharma Huasheng For US$12 Million 17
NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 18
NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 19
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 20
Jointown Pharma To Acquire 49% Stake In NCPC International For US$9.7 Million 21
North China Pharmaceutical Group Corp – Key Competitors 22
North China Pharmaceutical Group Corp – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Key Facts 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
North China Pharma Announces Private Placement Of Common Stock For US$466 Million 11
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 12
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 13
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 14
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 15
North China Pharma Announces Public Offering Of Notes For US$73 Million 16
NCPC To Sell North China Pharma Huasheng For US$12 Million 17
NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 18
NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 19
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 20
Jointown Pharma To Acquire 49% Stake In NCPC International For US$9.7 Million 21
North China Pharmaceutical Group Corp, Key Competitors 22
North China Pharmaceutical Group Corp, Other Locations 23
North China Pharmaceutical Group Corp, Subsidiaries 23

★海外企業調査レポート[North China Pharmaceutical Group Corp-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Huaneng Group:発電所・企業SWOT分析
    China Huaneng Group - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Segafredo Zanetti S.p.A.:企業の戦略・SWOT・財務情報
    Segafredo Zanetti S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Segafredo Zanetti S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • BDO Unibank Inc:企業の戦略・SWOT・財務情報
    BDO Unibank Inc - Strategy, SWOT and Corporate Finance Report Summary BDO Unibank Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SI-Bone Inc (SIBN):医療機器:M&Aディール及び事業提携情報
    Summary SI-Bone Inc (SI-BONE) is a medical device company that develops, manufactures and distributes diagnosing and treating patients with SI joint disorders products and tools. The company offers medical devices for patients with low back issues, degenerative sacroiliitis, and SI joint disruptions …
  • New York City Health and Hospitals Corp:企業の戦略的SWOT分析
    New York City Health and Hospitals Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Nuclear Power Corporation of India Ltd-エネルギー分野:企業M&A・提携分析
    Summary Nuclear Power Corporation of India Ltd (NPCIL) designs, constructs, commissions and operates nuclear power reactors. It is controlled and governed by the Department of Atomic Energy (DAE), Government of India. The company generates power from nuclear with pressurized heavy water reactor, lig …
  • The Depository Trust & Clearing Corp:企業の戦略的SWOT分析
    The Depository Trust & Clearing Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • MegaChips Corp (6875):企業の財務・戦略的SWOT分析
    MegaChips Corp (6875) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Soil Machine Dynamics Ltd:企業の戦略的SWOT分析
    Soil Machine Dynamics Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Welcome Break Group Limited:企業の戦略・SWOT・財務情報
    Welcome Break Group Limited - Strategy, SWOT and Corporate Finance Report Summary Welcome Break Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Anthera Pharmaceuticals Inc:企業のM&A・事業提携・投資動向
    Anthera Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Anthera Pharmaceuticals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Fractyl Laboratories Inc:医療機器:M&Aディール及び事業提携情報
    Summary Fractyl Laboratories Inc (Fractyl) is a clinical-stage medical technology company that develops novel devices and procedures to overcome insulin resistance and restitute metabolic health. The company developed a device-based clinical platform to change the way of treating metabolic diseases. …
  • Mediaset SpA (MS)
    Mediaset SpA (MS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Evergreen Packaging Llc
    Evergreen Packaging Llc - Strategy, SWOT and Corporate Finance Report Summary Evergreen Packaging Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Hillenbrand, Inc.:企業の戦略・SWOT・財務情報
    Hillenbrand, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hillenbrand, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Formosa Laboratories Inc (4746):製薬・医療:M&Aディール及び事業提携情報
    Summary Formosa Laboratories Inc (Formosa Laboratories) is a producer of active pharmaceutical ingredients and UV-filters. The company’s active pharmaceutical ingredients include cholesterol and phosphate binders, anticancers, CNS agents, immunomodulators, MRI enhancing agents, anti-inflammatory and …
  • Denka Co Ltd (4061):企業の財務・戦略的SWOT分析
    Denka Co Ltd (4061) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Option NV (OPTI):企業の財務・戦略的SWOT分析
    Option NV (OPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Republic Airline, Inc.:企業の戦略・SWOT・財務情報
    Republic Airline, Inc. - Strategy, SWOT and Corporate Finance Report Summary Republic Airline, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • China Health Group Inc (8225):企業の財務・戦略的SWOT分析
    China Health Group Inc (8225) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆